Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Nine-month net loss widened to $46.404 million from $4.312 million, despite the narrower third-quarter loss.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aligos Therapeutics (ALGS) reported a narrower third-quarter 2026 net loss while advancing its clinical studies for chronic hepatitis B infection. Net loss was $21.86 million, or $2.09 per share, versus $31.537 million, or $3.04 per share, a year earlier. Research and development expenses fell to $18.892 million from $23.937 million, while general and administrative expenses rose.
Cash, cash equivalents and investments totaled $31.1 million at September 30, versus $77.8 million at December 31, 2025. Aligos expects cash and cash equivalents to fund planned operations into Q1 2027. Phase 2 B-SUPREME enrollment is complete, with 131 participants in the HBeAg-positive cohort and 114 in the HBeAg-negative cohort; topline results are expected in late Q3 2027. Partner Amoytop advanced ALG-170675 into Phase 1 studies in China and is funding current development costs there.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointQ3 2026 net loss narrowed to $21.86 million, or $2.09 per share, from $31.537 million, or $3.04.
- Moderate pointB-SUPREME enrollment completed with 131 HBeAg-positive and 114 HBeAg-negative participants.
- Moderate pointALG-170675 advanced into Phase 1 studies in China through partner Amoytop.
- Moderate pointAmoytop funds current China development costs; Aligos may use study data for regulatory filings and other purposes.
- Moderate pointNine-month 2026 licensing revenue reached $27.817 million, versus none a year earlier.
- Moderate pointNine-month 2026 operating loss narrowed to $50.709 million from $66.171 million a year earlier.
8 minor points
- Minor point70 B-SUPREME participants have completed 48 weeks of treatment.
- Minor point. Forward-looking: it has not happened yet and may not happen.B-SUPREME topline data for both cohorts are expected in late Q3 2027.
- Minor pointQ3 2026 customer revenue rose to $2.830 million from $0.741 million a year earlier.
- Minor pointQ3 2026 licensing revenue reached $39,000, versus none a year earlier.
- Minor pointQ3 2026 R&D expenses fell to $18.892 million from $23.937 million a year earlier.
- Minor pointQ3 2026 operating loss narrowed to $21.890 million from $28.361 million a year earlier.
- Minor pointQ3 2026 warrant fair-value income was $187,000, versus a $4.205 million loss a year earlier.
- Minor pointNine-month 2026 customer revenue rose to $5.660 million from $2.017 million a year earlier.
Negative
- Major pointNine-month 2026 net loss widened to $46.404 million, or $4.45 per share, from $4.312 million, or $0.44.
- Moderate pointCash, cash equivalents and investments fell to $31.1 million at September 30, from $77.8 million at December 31, 2025.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash runway extends into Q1 2027, based on Aligos’ expected funding of planned operations.
- Moderate pointNine-month 2026 R&D expenses rose to $66.294 million from $52.415 million a year earlier.
- Moderate pointStockholders’ equity fell to $11.306 million at September 30, 2026, from $53.545 million at December 31, 2025.
8 minor points
- Minor pointQ3 2026 G&A expenses rose to $5.867 million from $5.165 million a year earlier.
- Minor pointQ3 2026 interest and other income fell to $169,000 from $1.085 million a year earlier.
- Minor pointQ3 2026 income tax provision rose to $326,000 from $56,000 a year earlier.
- Minor pointNine-month 2026 G&A expenses rose to $17.892 million from $15.773 million a year earlier.
- Minor pointNine-month 2026 interest and other income fell to $1.201 million from $3.172 million a year earlier.
- Minor pointNine-month 2026 warrant fair-value income fell to $6.558 million from $58.971 million a year earlier.
- Minor pointNine-month 2026 income tax provision rose to $3.454 million from $284,000 a year earlier.
- Minor pointTotal liabilities rose to $35.883 million at September 30, 2026, from $34.988 million at December 31, 2025.
News Explained
The third-quarter results report adds a licensing-revenue line for the first nine months of 2026 and in Q3 2026.
Key Figures
- Enrollment by cohort
- 131 HBeAg+; 114 HBeAg− participants
- Phase 2 B-SUPREME study; enrollment completed
- Topline data timing
- Late Q3 2027
- Expected for both B-SUPREME cohorts
- Cash, cash equivalents and investments
- $31.1 million, compared with $77.8 million
- September 30, 2026 versus December 31, 2025
- Expected funding runway
- Into the first quarter of 2027
- Company estimate for planned operations
- Net loss
- $21.9 million, compared with $31.5 million
- Three months ended September 30, 2026 versus 2025
Previous Earnings Reports
-
Reported B-SUPREME enrollment completion, China designation, Amoytop license proceeds and Q4 2026 runway.
-
Reported ongoing B-SUPREME enrollment, cash runway, and Amoytop Greater China license terms.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
antisense oligonucleotide medical
stock-based compensation financial
common warrants financial
hbeag+ medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026.
“This past quarter we continued to advance our Phase 2 B-SUPREME study of pevifoscorvir sodium, which remains on track for the topline data readout in late Q3 2027,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “With enrollment complete and 70 participants having completed 48 weeks of treatment, the study continues to progress toward the anticipated topline data readout. We remain enthusiastic about pevifoscorvir sodium’s potential, as well as our ASO ALG-170675, which is currently in a Phase 1 study in China with our partner Amoytop. With these recent developments, we believe we are one step closer to our goal of bringing effective therapies to people living with chronic HBV infection.”
Recent Business Progress
Pipeline Updates
Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection
- The Phase 2 B-SUPREME study (NCT06963710) has completed enrollment with 131 participants enrolled in the HBeAg+ cohort (Part 1a) and 114 participants enrolled in the HBeAg- cohort (Part 2a).
- Topline data for both the HBeAg+ and HBeAg- cohorts are expected in late Q3 2027.
ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection
- Our partner Amoytop advanced ALG-170675 into Phase 1 clinical studies. Current costs for development in China are being funded by Amoytop, who maintain rights in Greater China.
- Under our agreement with Amoytop, Aligos may utilize data from these studies for regulatory filings and other purposes. Each party is responsible for their own development costs.
Financial Results for the Three Months Ended September 30, 2026
Cash, cash equivalents and investments totaled
Net loss for the three months ended September 30, 2026 was
Research and development (R&D) expenses for the three months ended September 30, 2026 were
General and administrative (G&A) expenses for the three months ended September 30, 2026 were
Interest and other income, net, was income of
Change in fair value of 2023 common warrants for the three months ended September 30, 2026, was income of
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements with respect to the expected timing of data readouts for the pevifoscorvir sodium B-SUPREME study; potential success of the Company’s development programs, including timing of the Company’s anticipated ASO clinical trials; statements regarding Amoytop’s success in developing the ASO and/or pevifoscorvir sodium in Greater China, including statements regarding timing and design of Amoytop’s anticipated clinical trials; and the company’s expectation that its cash, cash equivalents and investments provide sufficient funding of planned operations into the first quarter of 2027. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos’ ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, reliance on collaborators to succeed in their development efforts and to comply with their contractual obligations, changes in the competitive landscape and the impact of global events and other macroeconomic conditions on Aligos’ business. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission on November 6, 2026 and Aligos’ Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Investor Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
| Aligos Therapeutics, Inc | ||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||
| September 30, | September 30, | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Revenue from customers | $ | 2,830 | $ | 741 | $ | 5,660 | $ | 2,017 | ||||
| Revenue from licensing agreements | 39 | - | 27,817 | - | ||||||||
| Operating expenses: | ||||||||||||
| Research and development | 18,892 | 23,937 | 66,294 | 52,415 | ||||||||
| General and administrative | 5,867 | 5,165 | 17,892 | 15,773 | ||||||||
| Total operating expenses | 24,759 | 29,102 | 84,186 | 68,188 | ||||||||
| Loss from operations | (21,890 | ) | (28,361 | ) | (50,709 | ) | (66,171 | ) | ||||
| Interest and other income, net | 169 | 1,085 | 1,201 | 3,172 | ||||||||
| Change in fair value of 2023 common warrants | 187 | (4,205 | ) | 6,558 | 58,971 | |||||||
| Loss before income tax | (21,534 | ) | (31,481 | ) | (42,950 | ) | (4,028 | ) | ||||
| Income tax provision | (326 | ) | (56 | ) | (3,454 | ) | (284 | ) | ||||
| Net loss | $ | (21,860 | ) | $ | (31,537 | ) | $ | (46,404 | ) | $ | (4,312 | ) |
| Net loss per share, basic | $ | (2.09 | ) | $ | (3.04 | ) | $ | (4.45 | ) | $ | (0.44 | ) |
| Net loss per share, diluted | $ | (2.09 | ) | $ | (3.04 | ) | $ | (4.45 | ) | $ | (0.44 | ) |
| Weighted-average shares of common stock, basic | 10,461,954 | 10,369,535 | 10,432,125 | 9,716,895 | ||||||||
| Weighted-average shares of common stock, diluted | 10,461,954 | 10,369,535 | 10,432,125 | 9,716,895 | ||||||||
| Aligos Therapeutics, Inc. Condensed Consolidated Balance Sheets (In thousands) | |||||
| September 30, 2026 | December 31, 2025 | ||||
| (Unaudited) | (Audited)(1) | ||||
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 31,094 | $ | 18,303 | |
| Short-term investments | - | 59,541 | |||
| Other current assets | 3,588 | 5,018 | |||
| Total current assets | 34,682 | 82,862 | |||
| Other assets | 12,507 | 5,671 | |||
| Total assets | $ | 47,189 | $ | 88,533 | |
| Liabilities and Stockholders’ Equity | |||||
| Current liabilities | $ | 19,600 | $ | 21,233 | |
| Other liabilities, noncurrent | 16,283 | 13,755 | |||
| Total liabilities | 35,883 | 34,988 | |||
| Total stockholders’ equity | 11,306 | 53,545 | |||
| Total liabilities and stockholders’ equity | $ | 47,189 | $ | 88,533 | |
_____________________________________________
(1) The condensed consolidated balance sheet as of December 31, 2025 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Aligos expect B-SUPREME Phase 2 results?
Aligos expects topline data in late Q3 2027 for both the HBeAg-positive and HBeAg-negative cohorts. Enrollment is complete, with 131 participants in the positive cohort and 114 in the negative cohort.
How long does Aligos expect its cash to fund operations?
Aligos expects its cash and cash equivalents to fund planned operations into the first quarter of 2027. Cash, cash equivalents and investments totaled $31.1 million at September 30, 2026, compared with $77.8 million at December 31, 2025.
What rights does Aligos have to ALG-170675 data from Amoytop’s China studies?
Aligos may use data from Amoytop’s studies for regulatory filings and other purposes. Amoytop maintains rights in Greater China and funds current development costs in China. Each party is responsible for its own development costs.
Why did Aligos’ third-quarter 2026 operating expense categories change?
Aligos attributes lower R&D expenses primarily to decreased third-party expenses for the pevifoscorvir sodium Phase 2 trial, and higher G&A expenses primarily to increased legal and related expenses. R&D expenses were $18.892 million, versus $23.937 million; G&A expenses were $5.867 million, versus $5.165 million a year earlier.